Roth Capital initiated coverage on BioRestorative Therapies with a new price target
$BRTX
Managed Health Care
Health Care
Roth Capital initiated coverage of BioRestorative Therapies with a rating of Buy and set a new price target of $37.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/1/2021 | $37.00 | Buy | Roth Capital |
4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
SCHEDULE 13D/A - BioRestorative Therapies, Inc. (0001505497) (Subject)
8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)
8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)
Roth Capital initiated coverage of BioRestorative Therapies with a rating of Buy and set a new price target of $37.00
– BRTX-100 is the first and only stem cell product candidate cleared to be evaluated in the cervical degenerative disc disease setting – – IND clearance expands Company's advanced clinical pipeline for BRTX-100 treatment of both chronic lower back and neck pain – – Company to host webcasted conference call today at 10:30am EST – MELVILLE, N.Y., Feb. 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug ("IND") application f
MELVILLE, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, announced today that it has changed the time for its previously announced webcasted conference call to discuss its pipeline update. The Company will now host the call at 10:30am EST on Thursday, February 27, 2025. To participate in the conference call by telephone, please dial 888-506-0062 (United States) or 973-528-0011 (International), participant access code 440089. The call will also be broadcast live and archived on the Investor section of the Comp
MELVILLE, N.Y., Feb. 25, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that it expects to provide a positive clinical pipeline update before market open on Thursday, February 27, 2025. "We very much look forward to updating investors on some recent meaningful key developments with respect to our clinical pipeline and review some additional positive events related to BRTX-100 on Thursday," said Lance Alstodt, Chief Executive Officer of BioRestorative. "We are thrilled to be in a position that reflects
SC 13D/A - BioRestorative Therapies, Inc. (0001505497) (Subject)
SC 13D/A - BioRestorative Therapies, Inc. (0001505497) (Subject)
SC 13D/A - BioRestorative Therapies, Inc. (0001505497) (Subject)
4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
– BRTX-100 is the first and only stem cell product candidate cleared to be evaluated in the cervical degenerative disc disease setting – – IND clearance expands Company's advanced clinical pipeline for BRTX-100 treatment of both chronic lower back and neck pain – – Company to host webcasted conference call today at 10:30am EST – MELVILLE, N.Y., Feb. 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug ("IND") application f
MELVILLE, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, announced today that it has changed the time for its previously announced webcasted conference call to discuss its pipeline update. The Company will now host the call at 10:30am EST on Thursday, February 27, 2025. To participate in the conference call by telephone, please dial 888-506-0062 (United States) or 973-528-0011 (International), participant access code 440089. The call will also be broadcast live and archived on the Investor section of the Comp
MELVILLE, N.Y., Feb. 25, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that it expects to provide a positive clinical pipeline update before market open on Thursday, February 27, 2025. "We very much look forward to updating investors on some recent meaningful key developments with respect to our clinical pipeline and review some additional positive events related to BRTX-100 on Thursday," said Lance Alstodt, Chief Executive Officer of BioRestorative. "We are thrilled to be in a position that reflects
MELVILLE, N.Y., Jan. 11, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the "Company" or "BioRestorative") (NASDAQ:BRTX), a life sciences company focused on stem cell-based therapies, today announced that Robert Paccasassi has been appointed Vice President of Quality Assurance/Regulatory Compliance. Mr. Paccasassi will lead quality initiatives through the next phase of the Company's growth as patient enrollment is initiated for the Phase 2 clinical trial to treat chronic lumbar disc disease. Mr. Paccasassi has over 25 years of biotech operations and combined experience in Quality Assurance, Regulatory Compliance, and Manufacturing. Prior to joining BioRestorative, Mr. Paccasassi
MELVILLE, N.Y., Nov. 10, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the "Company") (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced that it has appointed Robert Kristal to the position of Chief Financial Officer. Mr. Kristal brings an extensive array of strategic and financial markets experience to the Company, including a background in advising global public life sciences companies in corporate finance, operations management systems, and strategic collaborations. Mr. Kristal is an experienced and versatile Wall Street and Bay St. professional who has built teams in both institutional sales and equity research at firms which